Future Immunologic and Nanotechnology-Based Therapeutic Strategies in Rheumatoid Arthritis
Advances in Pharmacology and Therapeutics Journal · 16.06.2026
DOI: 10.18502/aptj.v5i4.21763 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Pharmacology and Therapeutics Journal, online erschienen am 16.06.2026. Verfasst von Mohammad Taher Tahoori.
Abstract (Originalsprache)
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, progressive cartilage destruction, and irreversible joint damage. Although conventional disease-modifying antirheumatic drugs (DMARDs), biologic agents, and targeted synthetic therapies such as Janus kinase (JAK) inhibitors have substantially improved disease outcomes, a significant proportion of patients fail to achieve sustained remission or develop treatment-related adverse effects (1). These limitations underscore the need for innovative therapeutic strategies that offer greater specificity, reduced systemic toxicity, and long-term immune regulation
Zitieren
APA
Tahoori, M. T. (2026). Future Immunologic and Nanotechnology-Based Therapeutic Strategies in Rheumatoid Arthritis. Advances in Pharmacology and Therapeutics Journal. https://doi.org/10.18502/aptj.v5i4.21763
Vancouver
Tahoori MT. Future Immunologic and Nanotechnology-Based Therapeutic Strategies in Rheumatoid Arthritis. Advances in Pharmacology and Therapeutics Journal. 2026. doi:10.18502/aptj.v5i4.21763
BibTeX
@article{Tahoori2026,
author = {Tahoori, Mohammad Taher},
title = {Future Immunologic and Nanotechnology-Based Therapeutic Strategies in Rheumatoid Arthritis},
journal = {Advances in Pharmacology and Therapeutics Journal},
year = {2026},
doi = {10.18502/aptj.v5i4.21763}
}
EUVIMED